A incidência do retinoblastoma é de 1 em 12,000 a 30,000 nascidos vivos.[16]Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990 Jan;108(1):128-32.
http://www.ncbi.nlm.nih.gov/pubmed/2288550?tool=bestpractice.com
[17]Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, et al. Retinoblastoma. Orphanet J Rare Dis. 2006 Aug 25;1:31.
https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-1-31
http://www.ncbi.nlm.nih.gov/pubmed/16934146?tool=bestpractice.com
Nos EUA, as taxas anuais de incidência de retinoblastoma (Programa Surveillance, Epidemiology and End Results [SEER]; 1973 a 2012) foram de aproximadamente 12 casos por 1 milhão de crianças com 4 anos de idade ou menos.[18]Fernandes AG, Pollock BD, Rabito FA. Retinoblastoma in the United States: a 40-year incidence and survival analysis. J Pediatr Ophthalmol Strabismus. 2018 May 1;55(3):182-8.
http://www.ncbi.nlm.nih.gov/pubmed/29257183?tool=bestpractice.com
[19]Wong JR, Tucker MA, Kleinerman RA, et al. Retinoblastoma incidence patterns in the US Surveillance, Epidemiology, and End Results program. JAMA Ophthalmol. 2014 Apr 1;132(4):478-83.
http://www.ncbi.nlm.nih.gov/pubmed/24577366?tool=bestpractice.com
No Reino Unido, entre 40 e 50 crianças são diagnosticadas por ano.[20]Childhood Eye Cancer Trust. Information about retinoblastoma for health professionals. [internet publication].
https://chect.org.uk/resources-2/hv
Em uma análise prospectiva baseada em grupos de 4064 pacientes com retinoblastoma, de 149 países, o Global Retinoblastoma Study Group relatou uma idade mediana no diagnóstico (entre 1º de janeiro de 2017 e 31 de dezembro de 2017) de 13.6 meses, em países de alta renda, e de 30 meses, em países de baixa renda.[21]Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Lancet Glob Health. 2022 Aug;10(8):e1128-40.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(22)00250-9/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/35839812?tool=bestpractice.com
Em uma análise transversal subsequente pelo Global Retinoblastoma Study Group, aproximadamente 50% dos pacientes de países de baixa renda tinham retinoblastoma extraocular no momento do diagnóstico (idade mediana de 30.5 meses quando do diagnóstico).[9]Global Retinoblastoma Study Group, Fabian ID, Abdallah E, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol. 2020 May 1;6(5):685-95.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2761957
http://www.ncbi.nlm.nih.gov/pubmed/32105305?tool=bestpractice.com
O estágio clínico de apresentação e a lateralidade do retinoblastoma podem influenciar a sobrevida. Estudos anteriores demonstraram que o retinoblastoma unilateral é caracterizado por apresentação tardia e pior desfecho ocular.[22]Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet. 2012 Apr 14;379(9824):1436-46.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61137-9/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/22414599?tool=bestpractice.com
[23]Mohammad M, Mehyar M, Halalsheh H, et al. The impact of tumor laterality (unilateral vs. bilateral) on presentation and management outcome in patients with retinoblastoma. J Clin Med. 2024 Apr 8;13(7):2146.
https://www.mdpi.com/2077-0383/13/7/2146
http://www.ncbi.nlm.nih.gov/pubmed/38610910?tool=bestpractice.com
O retinoblastoma unilateral é a forma mais comum da doença em países de renda baixa, média e alta.[9]Global Retinoblastoma Study Group, Fabian ID, Abdallah E, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol. 2020 May 1;6(5):685-95.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2761957
http://www.ncbi.nlm.nih.gov/pubmed/32105305?tool=bestpractice.com
[21]Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Lancet Glob Health. 2022 Aug;10(8):e1128-40.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(22)00250-9/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/35839812?tool=bestpractice.com